関連する実験動画
Updated: May 6, 2026

07:09
Isolation of Adipose Tissue Immune Cells
Published on: May 22, 2013
36.0K
痩せた男性と比較して肥満者における脂肪組織酸素圧力の増加は,インスリン抵抗性,脂肪組織毛細血管の障害,および炎症に伴います
Gijs H Goossens1, Alessandro Bizzarri, Nicolas Venteclef
1Department of Human Biology, NUTRIM School for Nutrition, Toxicology, and Metabolism, Maastricht University Medical Centre, PO Box 616, 6200 MD Maastricht, Netherlands. G.Goossens@maastrichtuniversity.nl
Circulation
|June 15, 2011
まとめ
脂肪組織の血流 (ATBF) は,脂肪組織 (AT) の酸素レベルを調節する. 肥満は,ATBFが低いにもかかわらず,より高いAT酸素と関連しており,インスリン抵抗性および炎症に寄与します.
科学分野:
- メタボリック生理学 メタボリック生理学
- 肥満に関する研究.
- アディポス組織生物学
背景:
- 肥満における脂肪組織 (AT) 機能不全は慢性炎症を誘発し,2型糖尿病と心血管疾患のリスクを高めます.
- 実験室内研究では,AT低酸素が炎症を引き起こす可能性があることが示唆されています.
- ATBF,AT酸素部分圧力 (AT P(O2),炎症,およびインスリン感受性の関係については,さらなる調査が必要である.
研究 の 目的:
- 脂肪組織の血流 (ATBF) がAT酸素部分圧 (AT P(O2) を調節し,AT炎症とインスリン感受性に影響を与えるという仮説を検証する.
主な方法:
- マイクロダイアリスを用いた継続的なAT P(O2) 監視のための光化学測定システムを開発しました.
- ATBFの薬理学的な (アンジオテンシンII,イソプレナリン) および生理学的 (グルコース摂取) 操作が,痩身や肥満の被験者におけるATP{\displaystyle P}{\displaystyle P}{\displaystyle O}{\displaystyle O}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle O}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\displaystyle P}{\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac {\frac}{\frac {\frac}{\frac}{\frac}\frac}{\frac}\frac}{\frac}\frac{\frac}\frac}).
主要な成果:
- アンジオテンシンIIはATBFとATPを減少させ,イソプレナリンは逆効果を示した.
- グルコースの摂取量は,痩せた人ではATBFとATP (O2) を増加させたが,肥満者では反応が鈍化した.
- 肥満患者は,AT酸素消費量の減少,インスリン抵抗性,AT毛細血管の障害,および炎症マーカーの増加に関連したATBFの低下にもかかわらず,AT高酸素症 (より高いATP(O2) を表した.
結論:
- ATBFはAT P(O2) の主要な規制機関である.
- 肥満は,AT高酸素症,AT酸素消費量の減少,インスリン抵抗性,毛細血管の機能低下,炎症の増大によって特徴付けられます.
- これらの発見は,ATBF,酸化,肥満における代謝機能障害の複雑な相互作用を強調しています.
関連する概念動画
Hypodermis
7.8K
The hypodermis (the subcutaneous layer or superficial fascia) is present directly below the dermis. It connects the skin to the underlying fascia (fibrous tissue) of the bones and muscles. It is not strictly a part of the skin, although the border between the hypodermis and dermis can be difficult to distinguish. The hypodermis consists of well-vascularized, loose, areolar connective tissue and adipose tissue, which functions as a mode of fat storage and provides insulation and cushioning for...
7.8K
Overview of Lipid Metabolism
7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
Obesity
1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
448
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
448
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
332
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
332
Type II Diabetes II: Pathophysiology
45
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
45

